JP2024542635A5 - - Google Patents

Info

Publication number
JP2024542635A5
JP2024542635A5 JP2024532179A JP2024532179A JP2024542635A5 JP 2024542635 A5 JP2024542635 A5 JP 2024542635A5 JP 2024532179 A JP2024532179 A JP 2024532179A JP 2024532179 A JP2024532179 A JP 2024532179A JP 2024542635 A5 JP2024542635 A5 JP 2024542635A5
Authority
JP
Japan
Application number
JP2024532179A
Other languages
Japanese (ja)
Other versions
JPWO2023102373A5 (https=
JP2024542635A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080555 external-priority patent/WO2023102373A1/en
Publication of JP2024542635A publication Critical patent/JP2024542635A/ja
Publication of JPWO2023102373A5 publication Critical patent/JPWO2023102373A5/ja
Publication of JP2024542635A5 publication Critical patent/JP2024542635A5/ja
Pending legal-status Critical Current

Links

JP2024532179A 2021-11-30 2022-11-29 ヒトメタニューモウイルスワクチン Pending JP2024542635A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284405P 2021-11-30 2021-11-30
US63/284,405 2021-11-30
PCT/US2022/080555 WO2023102373A1 (en) 2021-11-30 2022-11-29 Human metapneumovirus vaccines

Publications (3)

Publication Number Publication Date
JP2024542635A JP2024542635A (ja) 2024-11-15
JPWO2023102373A5 JPWO2023102373A5 (https=) 2025-12-08
JP2024542635A5 true JP2024542635A5 (https=) 2025-12-08

Family

ID=84602059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532179A Pending JP2024542635A (ja) 2021-11-30 2022-11-29 ヒトメタニューモウイルスワクチン

Country Status (13)

Country Link
US (1) US20230310571A1 (https=)
EP (1) EP4440608A1 (https=)
JP (1) JP2024542635A (https=)
KR (1) KR20240118798A (https=)
CN (1) CN118338911A (https=)
AR (1) AR127808A1 (https=)
AU (1) AU2022399571A1 (https=)
CA (1) CA3239417A1 (https=)
CO (1) CO2024007274A2 (https=)
IL (1) IL312997A (https=)
MX (1) MX2024006240A (https=)
TW (1) TW202340227A (https=)
WO (1) WO2023102373A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
JP2026504862A (ja) 2023-01-18 2026-02-10 ファイザー・インク 呼吸器疾患に対するワクチン
WO2025119162A1 (zh) * 2023-12-04 2025-06-12 深圳深信生物科技有限公司 偏肺病毒(mpv)疫苗
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025210592A1 (en) 2024-04-05 2025-10-09 Sanofi Pasteur Inc. Muscle cell lnp-mrna quality control assays
WO2025250938A2 (en) * 2024-05-31 2025-12-04 Modernatx, Inc. Respiratory syncytial virus and metapneumovirus vaccines
WO2026018181A1 (en) 2024-07-17 2026-01-22 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026027730A1 (en) * 2024-07-31 2026-02-05 Sanofi Modified h5 influenza hemagglutinin polypeptides and nucleic acids and uses thereof
CN121221752A (zh) * 2025-02-14 2025-12-30 北京悦康科创医药科技股份有限公司 一种膜融合抑制多肽在抗副黏病毒科病毒感染中的应用
CN119978144B (zh) * 2025-02-14 2025-10-17 嘉译生物医药(杭州)有限公司 一种hMPV病毒融合蛋白F变体、mRNA疫苗及其应用
CN119971017B (zh) * 2025-04-16 2025-08-05 北京华诺泰生物医药科技有限公司 一种hmpv疫苗组合物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500707A (en) 1980-02-29 1985-02-19 University Patents, Inc. Nucleosides useful in the preparation of polynucleotides
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5132418A (en) 1980-02-29 1992-07-21 University Patents, Inc. Process for preparing polynucleotides
US4973679A (en) 1981-03-27 1990-11-27 University Patents, Inc. Process for oligonucleo tide synthesis using phosphormidite intermediates
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
US4668777A (en) 1981-03-27 1987-05-26 University Patents, Inc. Phosphoramidite nucleoside compounds
US4401796A (en) 1981-04-30 1983-08-30 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US4373071A (en) 1981-04-30 1983-02-08 City Of Hope Research Institute Solid-phase synthesis of polynucleotides
US5153319A (en) 1986-03-31 1992-10-06 University Patents, Inc. Process for preparing polynucleotides
US5262530A (en) 1988-12-21 1993-11-16 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US5047524A (en) 1988-12-21 1991-09-10 Applied Biosystems, Inc. Automated system for polynucleotide synthesis and purification
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5700642A (en) 1995-05-22 1997-12-23 Sri International Oligonucleotide sizing using immobilized cleavable primers
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5684042A (en) 1997-01-10 1997-11-04 Medlogic Global Corporation Cyanoacrylate compositions comprising an antimicrobial agent
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
ATE356630T1 (de) 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
US8178098B2 (en) 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
AU2010264686A1 (en) * 2009-06-24 2012-01-19 Glaxosmithkline Biologicals S.A. Vaccine
HUE042177T2 (hu) 2009-12-01 2019-06-28 Translate Bio Inc Szteroidszármazék mRNS szállítására humán genetikai betegségekben
EP2519636B8 (en) 2009-12-28 2017-08-09 DSM IP Assets B.V. Production of hemagglutinin-neuraminidase protein in microalgae
IN2012DN06277A (https=) 2009-12-28 2015-09-25 Dsm Ip Assets Bv
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
KR102451116B1 (ko) 2011-10-27 2022-10-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, n-말단 상에 관능화된 아미노산 유도체
US10245229B2 (en) 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
CN105051213A (zh) 2013-03-14 2015-11-11 夏尔人类遗传性治疗公司 信使rna加帽效率的定量评估
US10130649B2 (en) 2013-03-15 2018-11-20 Translate Bio, Inc. Synergistic enhancement of the delivery of nucleic acids via blended formulations
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
KR102399799B1 (ko) 2013-12-30 2022-05-18 큐어백 아게 인공 핵산 분자
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
BR112016030852A2 (pt) 2014-07-02 2018-01-16 Shire Human Genetic Therapies encapsulação de rna mensageiro
DE202015010000U1 (de) 2014-12-12 2023-07-03 CureVac SE Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
ES2897823T3 (es) 2015-04-30 2022-03-02 Curevac Ag Poli(N)polimerasa inmovilizada
ES2949540T3 (es) 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
WO2018089801A1 (en) 2016-11-10 2018-05-17 Translate Bio, Inc. Improved process of preparing mrna-loaded lipid nanoparticles
MX2019005470A (es) 2016-11-10 2019-11-21 Translate Bio Inc Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm.
EP3558356A2 (en) * 2016-12-23 2019-10-30 CureVac AG Mers coronavirus vaccine
EP4003311A1 (en) 2019-07-23 2022-06-01 Translate Bio, Inc. Stable compositions of mrna-loaded lipid nanoparticles and processes of making

Similar Documents

Publication Publication Date Title
JP2024542635A5 (https=)
CL2025003637A1 (es) Anticuerpos anti-tgf-beta 1 latente y métodos de uso.
BR102022025291A2 (https=)
CL2025003847A1 (es) Composiciones adyuvantes en nanoemulsión para vacunas contra el papilomavirus humano.
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
CN307044356S (https=)
BY13164U (https=)
CN307044826S (https=)
BY13159U (https=)
CN307044273S (https=)
BY13158U (https=)
CN307045665S (https=)
BY23963C1 (https=)
BY13176U (https=)
BY13175U (https=)
BY13174U (https=)
BY13172U (https=)
BY13170U (https=)
CN307045964S (https=)
BY13169U (https=)
CN307046199S (https=)